|
Nov 7
|
Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ...
|
|
Nov 7
|
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
|
|
Oct 31
|
Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis
|
|
Oct 5
|
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
|
|
Sep 29
|
Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal
|
|
Apr 25
|
ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
|